Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Advent Venture Partners, founded in 1981, is one of Europe's oldest venture capital firms, based in the United Kingdom. The firm has a long-standing history of investing in technology and healthcare sectors, supporting innovative companies that drive significant impact. Over its four-decade history, Advent Venture Partners has transitioned its operations to Advent Life Sciences, which continues to build on its legacy in the life sciences sector.
As of its dissolution in December 2020, Advent Venture Partners managed a fund size of $120 million. The firm had a strong track record of notable exits, including companies like Farfetch, Algeta, and Santarus. Advent Venture Partners has historically focused on early to growth-stage investments, primarily in Europe and the United States, and has built a reputation for its strategic support to portfolio companies.
Advent Venture Partners has played a pivotal role in the development of many successful companies, and its legacy continues through Advent Life Sciences, which focuses on building innovative life sciences businesses across the UK, Europe, and the USA.
Advent Venture Partners invests in early to growth-stage companies, primarily within the technology and healthcare sectors. The firm emphasizes a geographical focus on Europe and the United States, targeting sectors such as healthcare, artificial intelligence, fintech, and biotechnology. Advent Venture Partners operates across multiple investment stages, including pre-seed, seed, seed-plus, series A, series B, series C, and growth equity.
The firm seeks to partner with entrepreneurs who are building innovative businesses capable of making a significant impact in their respective fields. Advent Venture Partners values strong leadership and a clear vision from founders, aiming to support companies that demonstrate potential for growth and scalability. The firm also emphasizes a partnership approach, working closely with portfolio companies to help them navigate competitive markets and achieve their goals.
Advent Venture Partners has a notable portfolio that includes several prominent companies:
The legacy portfolio also features significant exits, including:
David H. Hargreaves - Managing Partner. David has extensive experience in venture capital and has been instrumental in leading investments in technology and healthcare sectors.
Mark P. Evans - Partner. Mark brings a wealth of knowledge in early-stage investments and has a strong track record of supporting portfolio companies in their growth journeys.
Sophie M. Hargreaves - Principal. Sophie focuses on identifying promising investment opportunities and has a keen eye for innovative startups in the technology space.
Startups interested in pitching to Advent Venture Partners should submit their proposals through the contact form available on their website. A well-prepared pitch deck should include key information such as the business model, market analysis, team background, and financial projections.
Response times can vary, but founders can generally expect to hear back within a few weeks. Advent Venture Partners appreciates warm introductions, so leveraging connections within their network can enhance the chances of a successful pitch.
Advent Venture Partners has a legacy of notable exits, including the IPO of Farfetch in September 2018, which marked a significant milestone for the firm. Algeta was acquired by Bayer in 2014, further showcasing the firm's successful investment strategy in the healthcare sector. Santarus, another notable exit, contributed to the firm's strong track record in pharmaceuticals.
Although Advent Venture Partners was dissolved in December 2020, its successor, Advent Life Sciences, continues to operate and build on the legacy established by Advent Venture Partners. The transition to Advent Life Sciences marks a new chapter for the team, focusing on life sciences investments while maintaining the firm's commitment to supporting innovative companies.
What are Advent Venture Partners' investment criteria?
Advent Venture Partners focuses on early to growth-stage companies in the technology and healthcare sectors. They look for businesses that demonstrate strong leadership, innovative solutions, and significant growth potential.
How can startups apply or pitch to Advent Venture Partners?
Startups can reach out through the contact information provided on the Advent Venture Partners website. They typically prefer a well-structured pitch deck that outlines the business model, market opportunity, and team background.
What makes Advent Venture Partners different from other investors?
Advent Venture Partners has a long history in venture capital, with a strong focus on technology and healthcare sectors. Their extensive experience and established network provide valuable resources and insights to portfolio companies.
What is the geographical scope of Advent Venture Partners' investments?
The firm primarily invests in Europe and the United States, targeting innovative companies that can drive significant impact in their respective markets.
What is the typical check size for investments made by Advent Venture Partners?
Advent Venture Partners typically invests between £5 million and £15 million (approximately $9 million to $29 million) in their portfolio companies, depending on the stage and needs of the business.
What kind of post-investment involvement does Advent Venture Partners have?
Advent Venture Partners provides strategic support to its portfolio companies, leveraging its extensive network and industry expertise to help them scale and succeed in competitive markets.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.